Remove market-access understanding-politics-drug-pricing-united-states
article thumbnail

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

The Pharma Data

Access to Just – Evotec Biologics’ highly efficient drug substance development platform and manufacturing technology complements Sandoz capabilities, supporting expansion of the current pipeline from 15+ to 24 assets and the continued development of its early-stage biosimilar pipeline.

article thumbnail

What Matters Most: The Trends That Will Shape Pharma Marketing in 2022

Intouch Solutions

MUSICAL CHAIRS The Great Resignation, and other factors, are changing the makeup of every group within pharma marketing — manufacturers and marketers, agencies and partners, patients and caregivers, HCPs and staff. Both types of HCPs hold prescribing privileges everywhere in the United States – and increasingly globally, as well.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

The Pharma Data

The US Food and Drug Administration and European Medicines Agency are currently reviewing ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults . Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Trials 52
article thumbnail

Bristol Myers Squibb Reports Second Quarter 2020 Financial Results

The Pharma Data

Management believes that measuring revenue rates on a comparable pro forma basis is an appropriate way for investors to best understand the underlying performance of the business. All comparisons are made versus the same period in 2019 unless otherwise stated. Marketing, selling and administrative expenses increased 51% to $1.6

article thumbnail

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

The Pharma Data

Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019. “We Novartis today announced that the U.S.

article thumbnail

Ep. 005 – Dave Chase Podcast Transcript

Pharma Marketing Network

This is Don Langsdorf with the Pharma Marketing Network pleased to welcome today Dave Chase, co-founder of the Health Rosetta. We are now in a 20-yearlong economic depression for the working and middle class as a result of health care prices inflating, prices not cost. Don (PMN): Hi welcome. Good morning, Dave. Dave (HR): Sure.

HR 40
article thumbnail

COVID-19 Pandemic Coverage

XTalks

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. The price of that prize is incalculable. The United Kingdom is reporting over 301,000 confirmed cases and over 45,000 deaths.